Ferroptosis-associated lncRNA prognostic signature predicts prognosis and immune response in clear cell renal cell carcinoma

Sci Rep. 2023 Feb 6;13(1):2114. doi: 10.1038/s41598-023-29305-5.

Abstract

Clear cell Renal Cell Carcinoma (ccRCC), the most deadly and life-threatening tumor in the urinary system, has a dismal prognosis and a high risk of metastasizing. Regulation of ferroptosis is a prospective therapeutic target to eradicate malignant cells. Our objective was to seek ferroptosis-associated long non-coding RNAs (FALs) and developed a prediction signature for ccRCC. We extracted transcriptome data and clinical information from The Cancer Genome Atlas (TCGA) databases. Ferroptosis-associated genes (FAGs) were obtained from FerrDb database. A ferroptosis-associated lncRNA prognostic signature (FLPS) of ccRCC was generated utilizing univariate Cox regression, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression, sequentially, based on 8 lncRNAs (LINC00460, AC124854.1, AC084876.1, IGFL2-AS1, LINC00551, AC083967.1, AC073487.1, and LINC02446). The signature's independent predictive value for ccRCC was demonstrated using univariate and multivariate regression analysis (P < 0.05). Subsequently, by combining independent predictive factors, a prognostic nomogram was established. Immunity analysis proclaimed a striking difference in terms of cells, function, checkpoints, and ESTIMATE scores between low- and high-risk groups. Overall, the innovative signature of ferroptosis-associated signatures may have a considerable effect on the immune response and prognosis for ccRCC.

MeSH terms

  • Carcinoma*
  • Carcinoma, Renal Cell* / genetics
  • Ferroptosis* / genetics
  • Humans
  • Immunity
  • Kidney Neoplasms* / genetics
  • Prognosis
  • RNA, Long Noncoding* / genetics

Substances

  • RNA, Long Noncoding